AbCellera Biologics Inc. ABCL Investments - Amortized Cost Basis
Investments - Amortized Cost Basis at other companies
Other financials
Where this comes from
Reported directly by AbCellera Biologics Inc. in its filing.
Tagged under the XBRL concept us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount.
The official record: AbCellera Biologics Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about AbCellera Biologics Inc.'s investments - amortized cost basis.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is AbCellera Biologics Inc.'s investments - amortized cost basis?
- AbCellera Biologics Inc. (ABCL) reported investments - amortized cost basis of $32.5M in Q1 2026.
- How has AbCellera Biologics Inc.'s investments - amortized cost basis changed year-over-year?
- AbCellera Biologics Inc.'s investments - amortized cost basis increased by 0.6% year-over-year, from $32.3M to $32.5M.
- What is the long-term trend for AbCellera Biologics Inc.'s investments - amortized cost basis?
- Over 3 years (2022 to 2025), AbCellera Biologics Inc.'s investments - amortized cost basis has grown at a 20.7% compound annual growth rate (CAGR), from $18.5M to $32.5M.